Japan CAR-T Therapy Landscape
Japan CAR-T therapy - Competitive landscapeJapan pharma catching-up with global players… but a large gap remains Novartis AG (NOVN SE)’ Kymriah...
1.1k Views
Investment Thesis and Valuation
Key Drivers Royalty from Seebri / Ultibro and QVM149 (expected launch in FY20e) to peak at ¥ 4.86b in FY25e Majority of the potential milestones...
413 Views
Para IV Winners and Losers - July 2018
This month’s Para IV developments suggest that there is likely to be benefit to Par Pharma, Dr. Reddy'S Laboratories (DRRD IN) & Amneal...
294 Views